Information Provided By:
Fly News Breaks for February 27, 2020
VKTX
Feb 27, 2020 | 07:32 EDT
H.C. Wainwright analyst Joseph Pantginis lowered the firm's price target on Viking Therapeutics to $18 from $31 and keeps a Buy rating on the shares following the company's Q4 results. The analyst sees a limited number of key catalysts through 2020.